A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension

Trial Profile

A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 16 Aug 2017 Planned End Date changed from 1 Sep 2019 to 1 May 2019.
    • 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top